These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18758819)

  • 21. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
    Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
    Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
    Schmitt NC; Trivedi S; Ferris RL
    Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
    Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line.
    Grandis JR; Zeng Q; Drenning SD; Tweardy DJ
    Int J Oncol; 1998 Aug; 13(2):375-8. PubMed ID: 9664135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
    Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
    Klinghammer K; Otto R; Raguse JD; Albers AE; Tinhofer I; Fichtner I; Leser U; Keilholz U; Hoffmann J
    Int J Cancer; 2017 Sep; 141(6):1215-1221. PubMed ID: 28560858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
    Liu R; Zhang L; Yang J; Zhang X; Mikkelsen R; Song S; Zhou H
    PLoS One; 2015; 10(5):e0125928. PubMed ID: 25933118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests.
    Kriegs M; Kasten-Pisula U; Riepen B; Hoffer K; Struve N; Myllynen L; Braig F; Binder M; Rieckmann T; Grénman R; Petersen C; Dikomey E; Rothkamm K
    Oncotarget; 2016 Jul; 7(29):45122-45133. PubMed ID: 27281611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.
    Lei Y; Kansy BA; Li J; Cong L; Liu Y; Trivedi S; Wen H; Ting JP; Ouyang H; Ferris RL
    Oncogene; 2016 Sep; 35(36):4698-707. PubMed ID: 26876213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Niwa H; Wentzel AL; Li M; Gooding WE; Lui VW; Grandis JR
    Clin Cancer Res; 2003 Oct; 9(13):5028-35. PubMed ID: 14581378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.
    Sandulache VC; Skinner HD; Ow TJ; Zhang A; Xia X; Luchak JM; Wong LJ; Pickering CR; Zhou G; Myers JN
    Cancer; 2012 Feb; 118(3):711-21. PubMed ID: 21720999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
    Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
    Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.
    Bier H; Hoffmann T; Haas I; van Lierop A
    Cancer Immunol Immunother; 1998 May; 46(3):167-73. PubMed ID: 9625540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
    McLaughlin M; Barker HE; Khan AA; Pedersen M; Dillon M; Mansfield DC; Patel R; Kyula JN; Bhide SA; Newbold KL; Nutting CM; Harrington KJ
    BMC Cancer; 2017 Jan; 17(1):86. PubMed ID: 28143445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
    Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
    Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.
    López-Albaitero A; Ferris RL
    Arch Otolaryngol Head Neck Surg; 2007 Dec; 133(12):1277-81. PubMed ID: 18086972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.